Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
December 2017 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the December BNF eNewsletter.
Six new drug monographs have been added to the BNF in the last month, including - azetolizumab, glycerol phenylbutyrate, migalastat, and nusinersen.

This issue includes dose changes due to interactions for ibrutinib. We have included updated MHRA advice on gabapentin (Neurontin®): risk of severe respiratory depression, and clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus. You will also find NICE technology appraisals for paclitaxel, pembrolizumab, and sorafenib.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNF 74 - BNFC 2017-2018
BNF BNF for Children Update
Gabapentin (Neurontin®): risk of severe respiratory depression (MHRA advice)
For further information, see gabapentin.
Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus (MHRA advice)
For further information, see clozapine.
Glycerol phenylbutyrate: new drug monograph
For further information, see glycerol phenylbutyrate.
Migalastat: new drug monograph
For further information, see migalastat.
Nusinersen: new drug monograph
For further information, see nusinersen.
BNF Update
Azetolizumab: new drug monograph
For further information, see azetolizumab.
Parathyroid hormone: new drug monograph
For further information, see parathyroid hormone.
Dose changes
Ibrutinib [dose adjustments due to interactions]
For further information, see ibrutinib.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Sorafenib for treating advanced hepatocellular carcinoma.
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
Other changes
To review other changes in the BNF, click on changes.
I News
Reminder - help from CPPE with BNF 74
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 74. It comprises 10 practical case studies, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the September 2017 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2017 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2017 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.